Press release
Meningococcal Vaccine Market to Reach US$ 6.05 Billion by 2033 at 6.4% CAGR, Driven by Rising Disease Incidence and Expanded Immunization Programs | DataM Intelligence
Meningococcal Vaccine Market
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/meningococcal-vaccines-market?jd
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)
United States Key Industry Developments
☑️ January 2026: Sanofi S.A. expanded U.S. availability of Menactra and MenQuadfi with new adolescent and adult catch-up campaigns, securing broader CDC recommendations and insurance coverage.
☑️ January 2026: Pfizer Inc. reported strong uptake of Trumenba and MenB vaccines, launching enhanced educational initiatives with public health agencies to increase awareness of serogroup B protection.
☑️ December 2025: Merck & Co., Inc. advanced its MenQuadfi conjugate vaccine distribution, partnering with major retail pharmacies and specialty clinics for improved access in high-risk communities.
Japan Key Industry Developments
☑️ January 2026: Japanese health authorities expanded meningococcal vaccination guidelines, increasing uptake of quadrivalent and serogroup B vaccines in high-risk populations and travelers.
☑️ January 2026: Local and global vaccine manufacturers showcased updated conjugate and polysaccharide meningococcal vaccines at major Tokyo infectious disease conferences, focusing on safety and immunogenicity data.
☑️ December 2025: Growing integration of meningococcal vaccines in Japan's routine immunization and travel clinics, driven by rising awareness of invasive meningococcal disease risks.
Key Mergers and Acquisitions
✦ January 2026: Sanofi S.A. acquired a vaccine technology startup to enhance its meningococcal conjugate vaccine pipeline and manufacturing capabilities.
✦ December 2025: Pfizer Inc. completed a strategic acquisition of a next-generation meningococcal vaccine candidate developer to bolster its serogroup coverage and innovation.
✦ November 2025: Serum Institute of India Pvt. Ltd. secured a licensing agreement with a global vaccine partner to expand production of low-cost meningococcal vaccines for emerging markets.
Purchase the report to unlock market insights:
https://www.datamintelligence.com/buy-now-page?report=meningococcal-vaccines-market
Market Segmentation Analysis
By Type: Quadrivalent vaccines hold the largest share due to broad coverage against serogroups A, C, W, and Y; Monovalent vaccines grow steadily for targeted serogroup protection; Bivalent and Others expand for niche indications.
By Product Type: Conjugate Meningococcal Vaccines dominate with superior immunogenicity and long-term protection; Polysaccharide Meningococcal Vaccines remain significant for cost-effective mass campaigns; Serogroup Meningococcal Vaccines grow rapidly for specific disease strains.
By End-User: Hospitals lead with high-volume administration and specialized care; Specialty Clinics follow for targeted vaccination and follow-up; Public Health Agencies expand for immunization programs and outbreak response; Others include travel clinics and community health centers.
Regional Insights
North America commands the largest market share in the global Meningococcal Vaccine market, supported by high vaccination coverage, strong CDC recommendations for adolescents and high-risk groups, widespread use of conjugate and serogroup B vaccines, advanced healthcare infrastructure, and significant R&D investment by leading vaccine manufacturers driving innovation and access.
Asia-Pacific remains the fastest-growing region, fueled by rising meningococcal disease awareness, increasing routine and catch-up immunization programs in China, India, and Southeast Asia, expanding healthcare access, government initiatives for vaccine procurement, growing travel-related vaccination demand, and aggressive market entry by global and local producers focusing on cost-effective conjugate vaccines.
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/meningococcal-vaccines-market?jd
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)
Key Players
The market includes major global players such as Sanofi S.A., GlaxoSmithKline Inc., Merck & Co., Inc., Pfizer Inc., Bio-Med (P) Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co., Ltd., Incepta Pharmaceuticals Ltd., and others.
Key Highlights (Top 5 Key Players)
✦ Sanofi S.A. - Leading provider of meningococcal conjugate vaccines (Menactra, MenQuadfi), with strong global reach and focus on broad serogroup coverage for adolescents and high-risk populations.
✦ GlaxoSmithKline Inc. - Renowned for Bexsero (MenB vaccine), driving significant market share in serogroup B prevention and adolescent immunization programs.
✦ Merck & Co., Inc. - Dominant with MenQuadfi conjugate vaccine, emphasizing strong clinical evidence and expanded indications for meningococcal protection.
✦ Pfizer Inc. - Strong player with Trumenba (MenB vaccine), focusing on high-risk groups and innovative formulations for broader coverage.
✦ Serum Institute of India Pvt. Ltd. - Key producer of low-cost meningococcal vaccines, supporting global supply and access in emerging markets.
Unlock 360° Market Intelligence with DataM Intelligence Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd
Power your decisions with real time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape Analysis
✅ Company Profile Analysis
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updates
✅ Live Market & Pricing Trends
✅ Regulatory and Supply Chain Analysis
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Meningococcal Vaccine Market to Reach US$ 6.05 Billion by 2033 at 6.4% CAGR, Driven by Rising Disease Incidence and Expanded Immunization Programs | DataM Intelligence here
News-ID: 4366509 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
United States Thermoplastic Composites Market Supports Growth in Lightweight Mat …
DataM Intelligence has published a new research report on "Thermoplastic Composites Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Sample PDF Of This Report (Get…
Global Cold Chain Market Set for Strong Growth at 9.28% CAGR Through 2031, Led b …
The Global Cold Chain Market reached at a CAGR of 9.28% during the forecast period 2024-2031.
Market growth is driven by surging demand for perishable goods like pharmaceuticals, fresh produce, and frozen foods amid rising global trade and e-commerce. Expansion of the food and beverage sector, pharmaceutical cold storage needs for vaccines and biologics, and government investments in infrastructure further fuel momentum. Technological advancements such as IoT-enabled monitoring, automated warehouses, and…
Cognitive Automation Market to Reach US$ 26.0 Billion by 2031 at 11.6% CAGR; Nor …
The cognitive automation market reached US$ 11.1 billion in 2023 and is expected to reach US$ 26.0 billion by 2031, growing at a CAGR of 11.6% during the forecast period 2024-2031. Market growth is driven by the increasing adoption of AI-powered automation solutions that combine machine learning, natural language processing, and analytics to handle complex, decision-based business processes.
Enterprises across banking, healthcare, manufacturing, and retail are deploying cognitive automation to improve…
Durable Medical Equipment Market to Reach US$ 324.34 Billion by 2031 at 5.3% CAG …
According to DataM Intelligence, the global Durable Medical Equipment market reached US$ 215.50 billion in 2023 and is expected to reach US$ 324.34 billion by 2031, growing at a CAGR of 5.3% during the forecast period 2024-2031, driven by rapidly aging global population, increasing preference for home healthcare and personal mobility solutions, strong demand for monitoring & therapeutic devices, and significant growth in Asia-Pacific with expanding healthcare access and rising…
More Releases for Meningococcal
Impact Of Rising Healthcare Spending On Meningococcal Vaccines: An Emerging Driv …
The Meningococcal Vaccines Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Meningococcal Vaccines Market Size and Projected Growth Rate?
The market size for meningococcal vaccines has seen rapid expansion in the past few years. The market is forecasted to increase from $3.89 billion…
Meningococcal Vaccines Market: Combating Life-Threatening Infections
In recent years, the global Meningococcal Vaccines Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Meningococcal Vaccines Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including…
Meningococcal Vaccines Market
Meningococcal Vaccines Market 2022
The Meningococcal Vaccines Market is expected to grow on an unabashed note in the next decade. With a worldwide shortage of healthcare staff, the healthcare IT solutions comprising web-based staffing platforms are doing the rounds. The future scenario won't be any different. These platforms would show the gaps, i.e. actual dearth of healthcare personnel like nurse's doctors, technicians, lab workers, and clinicians, which would help the entire…
Meningococcal Vaccines Market Report Up to 2031
Visiongain has published a new report on Meningococcal Vaccines Market Report 2021-2031: Forecasts by Vaccine Type (Conjugate, Polysaccharide, Others), by End-user (Paediatric, Adult, Traveler), by Brand (Bexsero, Menactra, Menveo, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios.
Download Exclusive Sample of Report @ https://www.visiongain.com/report/meningococcal-vaccines-market-2021/#download_sampe_div
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations…
Global Meningococcal Vaccines Market Research Report
This report studies the global Meningococcal Vaccines market status and forecast, categorizes the global Meningococcal Vaccines market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report GlaxoSmithKline JN-International Medical Novartis International Sanofi Pfizer Baxter International Geographically, this report studies the top producers and…
Meningococcal Vaccines Market Growth by 2028 | GlaxoSmithKline, Polysaccharide M …
Partnerships between the private sector and public institutions have been the chief agenda of global public health initiatives. The last few years have witnessed an increase in several private-public partnerships specifically focussing on vaccine provision in developing countries. Partnerships like the International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control (ICG) help magnify the vaccine outreach to remote areas of the world with the maximum need. The governments of…
